In 2018, the share of women aged 50-75 years who had received a breast cancer screening in the past two years was lowest in Alaska (67.3 percent) and highest in Rhode Island (87 percent). This statistic displays the percentage of U.S. women aged 50-75 years who received a breast cancer screening in the past two years as of 2018.

Between 2022 and 2023, about **** percent of women aged 50 to 69 years in Italy had a mammogram. Preventive breast cancer screening through a mammogram every two years is most recommended for those aged 50 to 69 years. Between 2022 and 2023, breast cancer screening was much more common in the Northern Italian regions, with rates often above ** percent. Breast cancer screening over time Before 2020, when COVID-19 hit Italy, the share of women between 50 and 69 years undergoing breast cancer screening at least once in the previous two years, had an increasing trend overall. However, the share of women who underwent preventive examinations for breast cancer after 2019 had a considerable decrease compared to the previous years. As a matter of fact, in 2019 the share of women with breast cancer screening amounted to **** percent, while in 2020 it was **** and in 2021 dropped to **** percent. Cervical cancer screening In Italy, women between the ages of 25 and 64 years are recommended to do a cervical cancer screening every three years. Since 2008, the percentage of women aged 25 to 65 who underwent cervical cancer screening in the previous three years, fluctuated yearly from **** to ** percent. This peak was reached in 2019 and was followed by a steep decrease in 2020, in correspondence with the spread of COVID-19. Between 2022 and 2023, when the share of women with cervical cancer screening amounted to **** percent in Italy, geographical differences could be observed across the country: among Northern regions, with **** percent of women underwent this screening, while in Southern regions this share amounted to only 69.1percent.

Editor’s Choice

• Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.
• Breast cancer is the most common cancer among women worldwide. In 2020, there were about 2.3 million new cases of breast cancer diagnosed globally.
• Breast cancer is the leading cause of cancer-related deaths in women. In 2020, it was responsible for approximately 685,000 deaths worldwide.
• The survival rate of breast cancer has improved over the years. In the United States, the overall five-year survival rate of breast cancer is around 90%.
• The American Cancer Society recommends annual mammograms starting at age 40 for women at average risk.
• Although rare, breast cancer also occurs in men. Less than 1% of breast cancer cases are diagnosed in males.

(Source: WHO, American Cancer Society)

Basic Metadata

*Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

Rate: Number of new cases of breast cancer (per 100,000) diagnosed at the regional or distant stage among females.

Definition: Age-adjusted incidence rate of invasive breast cancer per 100,000 female population.

Data Sources:

(1) NJ State Cancer Registry, Dec 31, 2015 Analytic File, using NCI SEER*Stat ver 8.2.1 (www.seer.cancer.gov/seerstat)

(2) NJ population estimates as calculated by the NCI's SEER Program, released January 2015, http://www.seer.cancer.gov/popdata/download.html.

In 2023, there were approximately *** cases of breast cancer diagnosed per 100,000 women in Sweden. During 2021 the rate reached the highest annual rate of *** cases in the provided time interval, although there may have been some delay from 2020 when the COVID-19 pandemic stopped check-ups and screenings.

BackgroundEarlier studies of breast cancer, screening mammography, and mortality reduction may have inflated lifetime and long-term risk estimates for invasive breast cancer due to limitations in their data collection methods and interpretation.ObjectiveTo estimate the percentage of asymptomatic peri/postmenopausal women who will be diagnosed with a first invasive breast cancer over their next 25 years of life.MethodsA systematic review identified peer-reviewed published studies that: 1) enrolled no study participants with a history of invasive breast cancer; 2) specified the number of women enrolled; 3) reported the number of women diagnosed with a first invasive breast cancer; 4) did not overcount [count a woman multiple times]; and, 5) defined the length of follow-up. Data sources included PubMed, Cochrane Library, and an annotated library of 4,409 full-text menopause-related papers collected and reviewed by the first author from 1974 through 2008. Linear regression predicted incidence of first invasive breast cancer, based on follow-up duration in all studies that met the our inclusion criteria, and in a subset of these studies that included only women who were 1) at least 50 years old and 2) either at least 50 or less than 50 but surgically menopausal at enrollment.ResultsNineteen studies met the inclusion criteria. They included a total of 2,305,427 peri/postmenopasual women. The mean cumulative incidence rate of first invasive breast cancer increased by 0.20% for each year of age (95% CI: 0.17, 0.23; p < 0.01; R2 = 0.90). Over 25 years of follow-up, an estimated 94.55% of women will remain breast cancer-free (95% CI: 93.97, 95.13). In the 12 studies (n = 1,711,178) that enrolled only postmenopausal women, an estimated 0.23% of women will be diagnosed with a first invasive breast cancer each year (95% CI: 0.18, 0.28; p < 0.01, R2 = 0.88).ConclusionThe vast majority (99.75%) of screened asymptomatic peri/postmenopasual women will not be diagnosed with invasive breast cancer each year. Approximately 95% will not be diagnosed with invasive breast cancer during 25 years of follow-up. Women who receive clinical examinations, but do not have mammograms, will have higher cancer-free rates because innocuous positives (comprising 30-50% of mammography diagnoses) will remain undetected. Informed consent to asymptomatic women should include these results and consideration of the benefits of avoiding mammograms.

Financial overview and grant giving statistics of Women Against Breast Cancer

Source: Cancer Screening Database, HPA. Data by February 8, 2014. Note: 1. Breast cancer screening rate calculation method: Number of women aged 45-69 who have undergone breast cancer screening in the past 2 years divided by the population of women aged 45-69 in December of that year. 2. Since July 2004, breast cancer screening has been provided to women aged 50-69 every 2 years. From November 17, 2009, the service has been expanded to include women aged 45-69.

Introduction Clustered within the nomenclature of Asian American are numerous subgroups, each with their own ethnic heritage, cultural, and linguistic characteristics. An understanding of the prevailing health knowledge, attitudes, and screening behaviors of these subgroups is essential for creating population-specific health promotion programs. Methods Korean American women (123) completed baseline surveys of breast cancer knowledge, attitudes, and screening behaviors as part of an Asian grocery store-based breast cancer education program evaluation. Follow-up telephone surveys, initiated two weeks later, were completed by 93 women. Results Low adherence to the American Cancer Society's breast cancer screening guidelines and insufficient breast cancer knowledge were reported. Participants' receptiveness to the grocery store-based breast cancer education program underscores the importance of finding ways to reach Korean women with breast cancer early detection information and repeated cues for screening. The data also suggest that the Asian grocery store-based cancer education program being tested may have been effective in motivating a proportion of the women to schedule a breast cancer screening between the baseline and follow-up surveys. Conclusion The program offers a viable strategy to reach Korean women that addresses the language, cultural, transportation, and time barriers they face in accessing breast cancer early detection information.

Financial overview and grant giving statistics of Women of Color Breast Cancer Survivors Support Project

The U.S. states are divided into groups based on the rates at which women developed or died from breast cancer in 2013, which is the most recent year for which incidence data are available.

Background and aimThis study aims to analyze the worldwide prevalence, mortality rates, and disability-adjusted life years (DALYs) attributed to breast cancer in women between 1990 and 2019. Additionally, it seeks to forecast the future trends of these indicators related to the burden of breast cancer in women from 2020 to 2030.MethodsData from the Global Burden of Disease Study (GBD) 2019 was analyzed to determine the age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) of DALYs due to breast cancer in women across 204 countries and territories from 1990 to 2019. Socio-economic development levels of countries and regions were assessed using Socio-demographic Indexes, and trends in the burden of breast cancer in women worldwide from 2020 to 2030 were projected using generalized additive models (GAMs).ResultsThe estimated annual percentage change (EAPC) in the ASIR breast cancer in women globally was 0.36 from 1990 to 2019 and is expected to increase to 0.44 from 2020 to 2030. In 2019, the ASIR of breast cancer in women worldwide was 45.86 and is projected to reach 48.09 by 2030. The burden of breast cancer in women generally rises with age, with the highest burden expected in the 45–49 age group from 2020 to 2030. The fastest increase in burden is anticipated in Central sub-Saharan Africa (EAPC in the age-standardized death rate: 1.62, EAPC in the age-standardized DALY rate: 1.52), with the Solomon Islands (EAPC in the ASIR: 7.25) and China (EAPC in the ASIR: 2.83) projected to experience significant increases. Furthermore, a strong positive correlation was found between the ASIR breast cancer in women globally in 1990 and the projected rates for 2030 (r = 0.62).ConclusionThe anticipated increase in the ASIR of breast cancer in women globally by 2030 highlights the importance of focusing on women aged 45–49 in Central sub-Saharan Africa, Oceania, the Solomon Islands, and China. Initiatives such as breast cancer information registries, raising awareness of risk factors and incidence, and implementing universal screening programs and diagnostic tests are essential in reducing the burden of breast cancer and its associated morbidity and mortality.

The population of Middle Tennessee was assessed using publically available data collected in 2009 describing demographic and breast cancer-related characteristics of the population.*The value for each breast cancer risk factor was determined for each Middle Tennessee County, and counties were then ranked in numerical order from lowest to highest. The numerically ranked counties were then subdivided into quartiles, such that the three counties with the lowest risk factor values were placed in Quartile 1, and those with the highest were placed in Quartile 4. The range of risk factor values encompassed by each quartile are shown.1The percentage of the total female population in the county that is over the age of 50 years (a surrogate for menopause).2The breast cancer incidence per 100,000 women. 3Breast cancer mortality per 100,000 women.4The percentage of all breast cancers that were diagnosed at Stage IV.5The percentage of all breast cancers that were diagnosed without a prior mammographic screening.6The percentage of the female population lacking any form of health insurance.7The median household income.8The percentage of the population possessing higher than a high school level education.9The percentage of the population that is not Caucasian.

Deaths from breast cancer in females registered in the calendar year, directly standardized by age group, given as a rate per 100,000 registered female patients.

Breast cancer remains a significant health concern for women in the United States, with the risk increasing as women age. For women aged 30, the probability of developing invasive breast cancer in the next ten years is *** percent. However, this risk rises substantially to *** percent for women in their ***. The lifetime risk of developing invasive breast cancer for American women stands at **** percent, highlighting the importance of regular screenings and early detection. Prevalence and impact As of January 2022, approximately **** million women in the U.S. had been diagnosed with breast cancer and survived. While breast cancer is the most common type of cancer among women in the country, lung and bronchus cancer accounts for the highest number of cancer-related deaths. Despite this, breast cancer remains a leading cause of concern, with an estimated ******* new cases among women in 2025. The impact of breast cancer extends beyond those diagnosed, as a 2022 survey found that about a quarter of women reported they or a family member had a history of the disease. Trends and developments Encouragingly, breast cancer mortality rates have decreased over recent decades. In 2022, the death rate due to breast cancer was **** per 100,000 population, a significant improvement from **** per 100,000 in 1990. This decline is attributed to factors such as early detection, improved therapies, and increased awareness of risk factors. However, breast cancer remains the second most deadly form of cancer among women in the United States. In 2025, there were estimated to be around 42,170 deaths due to breast cancer among women in the United States.

Worldwide, breast cancer is the most common type of cancer in women and the second highest in terms of mortality rates.Diagnosis of breast cancer is performed when an abnormal lump is found (from self-examination or x-ray) or a tiny speck of calcium is seen (on an x-ray). After a suspicious lump is found, the doctor will conduct a diagnosis to determine whether it is cancerous and, if so, whether it has spread to other parts of the body. This breast cancer dataset was obtained from the University of Wisconsin Hospitals, Madison from Dr. William H. Wolberg.

Each variable was assessed for each ZIP code within each county. Based on The Pearson's Correlation between the indicated variables was calculated using datapoints obtained for each ZIP code within each county.

Source: Cancer Screening Database, HPA. Data by February 8, 2014. Note: 1. Breast cancer screening rate calculation method: Number of women aged 45-69 who have received breast cancer screening in the past 2 years / population of women aged 45-69 in December of that year. 2. Starting in July 2004, biennial mammography screening has been provided for women aged 50-69. As of November 17, 2009, the service has been expanded to include women aged 45-69.

Introduction

Breast Cancer Statistics: Breast cancer stands as one of the most widespread and significant health challenges affecting women across the globe. As the most commonly diagnosed cancer in women, it poses a critical public health issue with far-reaching clinical and societal consequences. Each year, millions of women and a notable number of men receive a breast cancer diagnosis, confronting not only medical treatment but also emotional and financial hardships.

The global incidence of breast cancer continues to rise, fueled by factors such as an aging population, lifestyle-related risks, and improved awareness and diagnostic capabilities. Despite progress in early detection, advanced therapies, and survivorship programs, stark disparities persist between high- and low-income countries, largely due to unequal access to quality care and resources.

This section comprehensively analyses breast cancer statistics, covering incidence, mortality, survival rates, geographical variations, and economic burden. A clear understanding of these trends is vital for guiding policy decisions, resource allocation, and advancing breast cancer research and care delivery efforts.